Research progress on fecal microbiota transplantation intervening intestinal mucosal barrier for treatment of ulcerative colitis based on the "Houchang Theory"

HUANG Shicai; FANG Dong; HAN Sufen; SHEN Yabei; GAO Lijie; DING Kang; JIANG Jinguang

doi:10.7619/jcmp.20244527

Journal of Clinical Medicine in Practice > 2025 > 29(7): 138-142, 148. > DOI: 10.7619/jcmp.20244527

HUANG Shicai, FANG Dong, HAN Sufen, SHEN Yabei, GAO Lijie, DING Kang, JIANG Jinguang. Research progress on fecal microbiota transplantation intervening intestinal mucosal barrier for treatment of ulcerative colitis based on the "Houchang Theory"[J]. Journal of Clinical Medicine in Practice, 2025, 29(7): 138-142, 148. DOI: 10.7619/jcmp.20244527

Citation:

PDF (875 KB)

Research progress on fecal microbiota transplantation intervening intestinal mucosal barrier for treatment of ulcerative colitis based on the "Houchang Theory"

1.
Anorectal Department, Kunshan Integrated Traditional Chinese and Western Medicine Hospital, Kunshan, Jiangsu, 215322
2.
Anorectal Center, Nanjing Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210001
3.
Anorectal Department, Suqian Traditional Chinese Medicine Hospital, Suqian, Jiangsu, 223805

More Information

Received Date: September 26, 2024
Revised Date: November 03, 2024

Graphical Abstract

Abstract

Abstract

Ulcerative colitis (UC) is a chronic autoimmune disease characterized primarily by impaired intestinal mucosal barrier function. Beneficial bacteria in the intestinal flora are crucial for maintaining intestinal function. Therefore, eliminating harmful bacteria, promoting the regeneration of beneficial bacteria, and reconstructing the intestinal mucosal barrier have become key strategies in the treatment of UC. The traditional Chinese medicine (TCM) "Houchang Theory" elucidates the mechanism of ulcer formation from the perspective of the "Zhimo" (lipid membrane) structure and achieves the purpose of treating UC by thickening the "Zhimo" through syndrome differentiation and treatment. This theory is consistent with the modern medical concept of reconstructing the intestinal mucosal barrier. Fecal microbiota transplantation (FMT), as a transformed product of TCM "Jinzhi" (liquid feces), has been proven to have significant efficacy in the treatment of UC. Based on the TCM "Houchang Theory" and from the perspective of the intestinal mucosal barrier, this article explored the mechanism of "Jinzhi" FMT in the treatment of UC and provides new strategies for clinical treatment.
- "Houchang Theory",
- fecal microbiota transplantation,
- "Jinzhi",
- intestinal flora,
- intestinal mucosal barrier,
- ulcerative colitis,
- biological barrier,
- autoimmune disease

FullText(HTML)

References (40)

References

[1]	DU L, HA C. Epidemiology and pathogenesis of ulcerative colitis[J]. Gastroenterol Clin North Am, 2020, 49(4): 643-654. doi: 10.1016/j.gtc.2020.07.005
[2]	VOOTUKURU N, VASUDEVAN A. Approach to loss of response to advanced therapies in inflammatory bowel disease[J]. World J Gastroenterol, 2024, 30(22): 2902-2919. doi: 10.3748/wjg.v30.i22.2902
[3]	BOPPANA K, ALMANSOURI N E, BAKKANNAVAR S, et al. Alterations in gut microbiota as early biomarkers for predicting inflammatory bowel disease onset and progression: a systematic review[J]. Cureus, 2024, 16(4): e58080.
[4]	张晓明, 柳越冬, 都静, 等. 中医学理论指导下的溃疡性结肠炎病因病机研究进展[J]. 中华中医药学刊, 2023, 41(9): 46-52.
[5]	李垚, 姜莉芸, 郑玉, 等. "厚肠" 探析[J]. 中医杂志, 2012, 53(8): 714-715.
[6]	ZHANG X, LUO X, TIAN L, et al. The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review[J]. Front Microbiol, 2023, 14: 1286429. doi: 10.3389/fmicb.2023.1286429
[7]	史瑞, 李军祥, 沈洪, 等. 溃疡性结肠炎中医诊疗专家共识(2023)[J]. 中华中医药杂志, 2024, 39(1): 288-296.
[8]	郑依玲, WANG D G Y, 马俊, 等. 黄龙汤的药用历史考证及性味归经与功能主治探讨[J]. 时珍国医国药, 2024, 35(2): 421-424.
[9]	许建峰, 王英絮, 田彤, 等. 中药金汁与粪菌移植的异同[J]. 中华中医药杂志, 2017, 32(8): 3414-3416.
[10]	谷雪松, 孙平良, 刘一东, 等. 基于金汁(粪菌移植)的历史及性味考探讨其应用前景[J]. 中华中医药杂志, 2021, 36(2): 1133-1135.
[11]	RATH T, ATREYA R, NEURATH M F. A spotlight on intestinal permeability and inflammatory bowel diseases[J]. Expert Rev Gastroenterol Hepatol, 2023, 17(9): 893-902. doi: 10.1080/17474124.2023.2242772
[12]	ZONG Y, MENG J, MAO T, et al. Repairing the intestinal mucosal barrier of traditional Chinese medicine for ulcerative colitis: a review[J]. Front Pharmacol, 2023, 14: 1273407. doi: 10.3389/fphar.2023.1273407
[13]	PAONE P, CANI P D. Mucus barrier, mucins and gut microbiota: the expected slimy partners?[J]. Gut, 2020, 69(12): 2232-2243. doi: 10.1136/gutjnl-2020-322260
[14]	付域泽, 焦帅, 张乃锋. 产丁酸菌的产酸机制及其在调控肠道健康中的作用研究进展[J]. 畜牧兽医学报, 2022, 53(12): 4148-4158.
[15]	徐海燕, 程月, 郭聪聪, 等. 植物乳杆菌对肠道吸收短链脂肪酸的调控作用[J]. 食品与发酵工业, 2024, 50(18): 24-32.
[16]	GUO Y, WANG F, MAO Y, et al. Influence of parturition on rumen bacteria and SCFAs in Holstein cows based on 16S rRNA sequencing and targeted metabolomics[J]. Animals: Basel, 2023, 13(5): 782. doi: 10.3390/ani13050782
[17]	ASHTON J J, BEATTIE R M. Inflammatory bowel disease: recent developments[J]. Arch Dis Child, 2024, 109(5): 370-376. doi: 10.1136/archdischild-2023-325668
[18]	YOSHIHARA T, OIKAWA Y, KATO T, et al. The protective effect of Bifidobacterium bifidum G9-1 against mucus degradation by Akkermansia muciniphila following small intestine injury caused by a proton pump inhibitor and aspirin[J]. Gut Microbes, 2020, 11(5): 1385-1404. doi: 10.1080/19490976.2020.1758290
[19]	ALLAM-NDOUL B, CASTONGUAY-PARADIS S, VEILLEUX A. Gut microbiota and intestinal trans-epithelial permeability[J]. Int J Mol Sci, 2020, 21(17): E6402. doi: 10.3390/ijms21176402
[20]	SHIN S Y, KIM Y, KIM W S, et al. Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease[J]. Intest Res, 2023, 21(1): 148-160. doi: 10.5217/ir.2021.00168
[21]	LEE J G, HAN D S, JO S V, et al. Characteristics and pathogenic role of adherent-invasive Escherichia coli in inflammatory bowel disease: Potential impact on clinical outcomes[J]. PLoS One, 2019, 14(4): e0216165. doi: 10.1371/journal.pone.0216165
[22]	KIU R, TREVEIL A, HARNISCH L C, et al. Bifidobacterium breve UCC2003 induces a distinct global transcriptomic program in neonatal murine intestinal epithelial cells[J]. iScience, 2020, 23(7): 101336. doi: 10.1016/j.isci.2020.101336
[23]	TAVOUKJIAN V. Faecal microbiota transplantation for the decolonization of antibiotic-resistant bacteria in the gut: a systematic review and meta-analysis[J]. J Hosp Infect, 2019, 102(2): 174-188. doi: 10.1016/j.jhin.2019.03.010
[24]	FANG J, WANG H, ZHOU Y P, et al. Slimy partners: the mucus barrier and gut microbiome in ulcerative colitis[J]. Exp Mol Med, 2021, 53: 772-787. doi: 10.1038/s12276-021-00617-8
[25]	金铭, 蒋灿灿. 黏蛋白MUC2的糖基单一化对Escherichia侵袭力及代谢功能影响及其参与溃疡性结肠炎发病机制研究[J]. 实用临床医药杂志, 2023, 27(2): 28-34. doi: 10.7619/jcmp.20222884
[26]	GOO N, BAE H J, PARK K, et al. The effect of fecal microbiota transplantation on autistic-like behaviors in Fmr1 KO mice[J]. Life Sci, 2020, 262: 118497. doi: 10.1016/j.lfs.2020.118497
[27]	ANTUSHEVICH H. Fecal microbiota transplantation in disease therapy[J]. Clin Chim Acta, 2020, 503: 90-98. doi: 10.1016/j.cca.2019.12.010
[28]	CHEN Q, FAN Y, ZHANG B, et al. Capsulized fecal microbiota transplantation induces remission in patients with ulcerative colitis by gut microbial colonization and metabolite regulation[J]. Microbiol Spectr, 2023, 11(3): e0415222. doi: 10.1128/spectrum.04152-22
[29]	韩素芬, 黄士财, 章阳, 等. 葛根芩连汤加减联合气药灌肠途径粪菌移植治疗大肠湿热型溃疡性结肠炎的疗效及肠道菌群变化观察[J]. 四川中医, 2022, 40(10): 98-101.
[30]	王志斌, 陈晨, 郭一, 等. 清肠温中方治疗轻中度溃疡性结肠炎的临床研究[J]. 中国中西医结合杂志, 2018, 38(1): 15-19.
[31]	孙中美, 李军祥, 路琼琼, 等. 清肠温中方联合粪菌移植对溃疡性结肠炎小鼠肠黏膜免疫的调控作用[J]. 西部中医药, 2024, 37(2): 9-13.
[32]	孙中美, 李军祥, 赵兴杰, 等. 清肠温中方联合粪菌移植对DSS诱导的溃疡性结肠炎大鼠肠黏膜的保护作用及其机制研究[J]. 中国中医急症, 2019, 28(7): 1221-1225.
[33]	HUANG D, WANG Y M, XU C L, et al. Colon-targeted hydroxyethyl starch-curcumin microspheres with high loading capacity ameliorate ulcerative colitis via alleviating oxidative stress, regulating inflammation, and modulating gut microbiota[J]. Int J Biol Macromol, 2024, 266: 131107. doi: 10.1016/j.ijbiomac.2024.131107
[34]	邹俊, 李俊杰, 程芳芳, 等. 姜黄素重建肠道微生态环境改善溃疡性结肠炎小鼠机制研究[J]. 浙江临床医学, 2023, 25(8): 1147-1150.
[35]	刘扬, 路明, 洪文, 等. 姜黄素联合粪菌移植对DSS诱导的小鼠溃疡性结肠炎的改善作用[J]. 吉林大学学报: 医学版, 2024, 50(1): : 136-142.
[36]	王新婷. 艾灸干预粪菌移植供体对其受体溃疡性结肠炎小鼠的疗效影响[D]. 北京: 北京中医药大学, 2022.
[37]	周从顺, 韩宇, 张彩凤, 等. 粪菌移植联合传统药物治疗溃疡性结肠炎对临床疗效及对血清学指标的影响[J]. 中国微生态学杂志, 2022, 34(3): 327-331, 337.
[38]	张喜云. 粪菌移植联合美沙拉嗪肠溶片治疗溃疡性结肠炎患者的效果[J]. 中国民康医学, 2023, 35(6): 59-61, 65.
[39]	孙滨滨, 王帅, 吴京伟, 等. 粪菌移植联合美沙拉嗪治疗大肠湿热型溃疡性结肠炎临床研究[J]. 中国中西医结合消化杂志, 2018, 26(11): 897-902.
[40]	孙莉莉, 薛青. 粪微生态移植联合柳氮磺吡啶对溃疡性结肠炎患者血清炎症因子及T细胞亚群的影响[J]. 临床输血与检验, 2021, 23(4): 497-501.

Cited By

Cited by

Periodical cited type(2)

1.	王依玟，史亚军，孟倩，白敏，崔娜，文爱东，王婧雯，丁一. 基于数据挖掘研究中医药治疗缺血性脑血管疾病的用药规律. 空军军医大学学报. 2024(09): 1042-1048+1054 .
2.	徐文立，段小花，陈普，杨丽萍. 针药结合治疗缺血性脑卒中的研究进展. 云南中医中药杂志. 2023(10): 63-69 .

Other cited types(1)

Get Citation

PDF

XML

Article views (37) PDF downloads (10) Cited by(3)

Turn off MathJax

Article Contents

Abstract

References

Research progress on fecal microbiota transplantation intervening intestinal mucosal barrier for treatment of ulcerative colitis based on the "Houchang Theory"

Abstract

References

Cited by

Periodical cited type(2)

Other cited types(1)

Catalog

Export File

Citation

Format

Content